Abstract
The donation of Mectizan® by Merck & Co Inc. in 1987 “as much as was needed for as long as was needed for onchocerciasis control” was a major change from traditional corporate drug donations. The company realised that those who needed the drug most would never be able to purchase it, and so gave it away. The donation enabled the Onchocerciasis Control Programme in West Africa to add Mectizan distribution to its ongoing control strategy. For the first time there was hope for those living in other areas of Africa, Latin America and Yemen. Governments and non-governmental development organizations quickly got together to begin treatment in these new areas. Two new programmes and partnerships were created; the African Programme for Onchocerciasis Control and the Onchocerciasis Elimination Programme for the Americas. These programmes have been in the forefront of developing new strategies, including the Community Directed approach, which has now expanded into other disease control programmes at the community level, such as Vitamin A distribution and malaria control. This donation has led not only to the probability of elimination of onchocerciasis in the Americas in the near future, but is stimulating approaches to the elimination in Africa, in areas considered impossible five years ago. Other major pharmaceutical donations have followed, initiating the plan to eliminate lymphatic filariasis worldwide, and also stimulating interest in controlling other “neglected tropical diseases,” which affect the poorest billion of the world’s population, making this now a reality.
Keywords: Community directed interventions, ivermectin, lymphatic filariasis, neglected tropical diseases, onchocerciasis
Current Pharmaceutical Biotechnology
Title:Beyond Providing Drugs: the Mectizan® Donation Stimulates New Strategies in Service Delivery and in Strengthening Health Systems
Volume: 13 Issue: 6
Author(s): Adrian Hopkins
Affiliation:
Keywords: Community directed interventions, ivermectin, lymphatic filariasis, neglected tropical diseases, onchocerciasis
Abstract: The donation of Mectizan® by Merck & Co Inc. in 1987 “as much as was needed for as long as was needed for onchocerciasis control” was a major change from traditional corporate drug donations. The company realised that those who needed the drug most would never be able to purchase it, and so gave it away. The donation enabled the Onchocerciasis Control Programme in West Africa to add Mectizan distribution to its ongoing control strategy. For the first time there was hope for those living in other areas of Africa, Latin America and Yemen. Governments and non-governmental development organizations quickly got together to begin treatment in these new areas. Two new programmes and partnerships were created; the African Programme for Onchocerciasis Control and the Onchocerciasis Elimination Programme for the Americas. These programmes have been in the forefront of developing new strategies, including the Community Directed approach, which has now expanded into other disease control programmes at the community level, such as Vitamin A distribution and malaria control. This donation has led not only to the probability of elimination of onchocerciasis in the Americas in the near future, but is stimulating approaches to the elimination in Africa, in areas considered impossible five years ago. Other major pharmaceutical donations have followed, initiating the plan to eliminate lymphatic filariasis worldwide, and also stimulating interest in controlling other “neglected tropical diseases,” which affect the poorest billion of the world’s population, making this now a reality.
Export Options
About this article
Cite this article as:
Hopkins Adrian, Beyond Providing Drugs: the Mectizan® Donation Stimulates New Strategies in Service Delivery and in Strengthening Health Systems, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399220
DOI https://dx.doi.org/10.2174/138920112800399220 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cost-Effectiveness of Antiretroviral Therapy for Prevention
Current HIV Research The IL-17 Family of Cytokines - Applications in Respiratory Medicine and Allergology
Recent Patents on Inflammation & Allergy Drug Discovery Design and Synthesis of (<i>E</i>)-4-(2-Phenyl-2<i>H</i>-chromen-3-yl)but-3-en-2-ones and Evaluation of their <i>In Vitro</i> Antimicrobial Activity
Letters in Organic Chemistry Antibacterial Activities of Flavonoids: Structure-Activity Relationship and Mechanism
Current Medicinal Chemistry Preparation and Antitubercular Activities of Palindromic Hydrazinecarbothioamides and Carbonothioic Dihydrazides
Letters in Drug Design & Discovery Cells of the Macrophage Lineage and their Role in the Pathogenesis of HIV-1 Infection: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Design and Synthesis of Novel Oxadiazole and Diphenyl Ether Hydrazone Derivatives of Coumarin as Potential Antibacterial Agents
Current Bioactive Compounds Non-Invasive Immunization on the Skin Using DNA Vaccine
Current Drug Delivery [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Design, Synthesis and In Vitro Anti-microbial Evaluation of Ethylene/ Propylene-1H-1,2,3-Triazole-4-Methylene-tethered Isatin-coumarin Hybrids
Current Topics in Medicinal Chemistry Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates
Current Drug Discovery Technologies Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Quality-by-design Enabled Chitosan Nanoparticles for Antitubercular Therapy: Formulation, Statistical Optimization, and <i>In Vitro</i> Characterization
Current Drug Therapy Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes
Current Molecular Medicine Transcription Analysis and Small Non-Protein Coding RNAs Associated with Bacterial Ribosomal Protein Operons
Current Medicinal Chemistry Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers
Current Medicinal Chemistry Insight View on Synthetic Strategies and Biological Applications of Pyrimidobenzothiazoles
Mini-Reviews in Organic Chemistry Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets Telemedicine, Genomics and Personalized Medicine: Synergies and Challenges
Current Pharmacogenomics and Personalized Medicine The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine